Five-aminosalicylic acid: An update for the reappraisal of an old drug

Cristiana Perrotta, Paolo Pellegrino, Eliana Moroni, Clara De Palma, Davide Cervia, Piergiorgio Danelli, Emilio Clementi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Inflammatory bowel disease (IBD) comprises several conditions with chronic or recurring immune response and inflammation of the gastrointestinal apparatus, of which ulcerative colitis and Crohn's disease are the commonest forms. This disease has a significant prevalence and it is of an unknown aethiology. Five-aminosalicylic acid (5-ASA) and its derivatives are among the oldest drugs approved for the treatment of the IBD. In this review we reapprise aspects of 5-ASA mechanism of action, safety, and efficacy that in our opinion make it a valuable drug that can be fruitfully tailored in personalised treatments as a therapeutic option alongside other immune-modifying agents.

Original languageEnglish
Article number456895
JournalGastroenterology Research and Practice
Volume2015
DOIs
Publication statusPublished - Jan 21 2015

Fingerprint

Aminosalicylic Acid
Inflammatory Bowel Diseases
Mesalamine
Ulcerative Colitis
Crohn Disease
Pharmaceutical Preparations
Inflammation
Safety
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Perrotta, C., Pellegrino, P., Moroni, E., De Palma, C., Cervia, D., Danelli, P., & Clementi, E. (2015). Five-aminosalicylic acid: An update for the reappraisal of an old drug. Gastroenterology Research and Practice, 2015, [456895]. https://doi.org/10.1155/2015/456895

Five-aminosalicylic acid : An update for the reappraisal of an old drug. / Perrotta, Cristiana; Pellegrino, Paolo; Moroni, Eliana; De Palma, Clara; Cervia, Davide; Danelli, Piergiorgio; Clementi, Emilio.

In: Gastroenterology Research and Practice, Vol. 2015, 456895, 21.01.2015.

Research output: Contribution to journalArticle

Perrotta, C, Pellegrino, P, Moroni, E, De Palma, C, Cervia, D, Danelli, P & Clementi, E 2015, 'Five-aminosalicylic acid: An update for the reappraisal of an old drug', Gastroenterology Research and Practice, vol. 2015, 456895. https://doi.org/10.1155/2015/456895
Perrotta C, Pellegrino P, Moroni E, De Palma C, Cervia D, Danelli P et al. Five-aminosalicylic acid: An update for the reappraisal of an old drug. Gastroenterology Research and Practice. 2015 Jan 21;2015. 456895. https://doi.org/10.1155/2015/456895
Perrotta, Cristiana ; Pellegrino, Paolo ; Moroni, Eliana ; De Palma, Clara ; Cervia, Davide ; Danelli, Piergiorgio ; Clementi, Emilio. / Five-aminosalicylic acid : An update for the reappraisal of an old drug. In: Gastroenterology Research and Practice. 2015 ; Vol. 2015.
@article{c7aec3a9ffeb4f189d700e98271d6da8,
title = "Five-aminosalicylic acid: An update for the reappraisal of an old drug",
abstract = "Inflammatory bowel disease (IBD) comprises several conditions with chronic or recurring immune response and inflammation of the gastrointestinal apparatus, of which ulcerative colitis and Crohn's disease are the commonest forms. This disease has a significant prevalence and it is of an unknown aethiology. Five-aminosalicylic acid (5-ASA) and its derivatives are among the oldest drugs approved for the treatment of the IBD. In this review we reapprise aspects of 5-ASA mechanism of action, safety, and efficacy that in our opinion make it a valuable drug that can be fruitfully tailored in personalised treatments as a therapeutic option alongside other immune-modifying agents.",
author = "Cristiana Perrotta and Paolo Pellegrino and Eliana Moroni and {De Palma}, Clara and Davide Cervia and Piergiorgio Danelli and Emilio Clementi",
year = "2015",
month = "1",
day = "21",
doi = "10.1155/2015/456895",
language = "English",
volume = "2015",
journal = "Gastroenterology Research and Practice",
issn = "1687-6121",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Five-aminosalicylic acid

T2 - An update for the reappraisal of an old drug

AU - Perrotta, Cristiana

AU - Pellegrino, Paolo

AU - Moroni, Eliana

AU - De Palma, Clara

AU - Cervia, Davide

AU - Danelli, Piergiorgio

AU - Clementi, Emilio

PY - 2015/1/21

Y1 - 2015/1/21

N2 - Inflammatory bowel disease (IBD) comprises several conditions with chronic or recurring immune response and inflammation of the gastrointestinal apparatus, of which ulcerative colitis and Crohn's disease are the commonest forms. This disease has a significant prevalence and it is of an unknown aethiology. Five-aminosalicylic acid (5-ASA) and its derivatives are among the oldest drugs approved for the treatment of the IBD. In this review we reapprise aspects of 5-ASA mechanism of action, safety, and efficacy that in our opinion make it a valuable drug that can be fruitfully tailored in personalised treatments as a therapeutic option alongside other immune-modifying agents.

AB - Inflammatory bowel disease (IBD) comprises several conditions with chronic or recurring immune response and inflammation of the gastrointestinal apparatus, of which ulcerative colitis and Crohn's disease are the commonest forms. This disease has a significant prevalence and it is of an unknown aethiology. Five-aminosalicylic acid (5-ASA) and its derivatives are among the oldest drugs approved for the treatment of the IBD. In this review we reapprise aspects of 5-ASA mechanism of action, safety, and efficacy that in our opinion make it a valuable drug that can be fruitfully tailored in personalised treatments as a therapeutic option alongside other immune-modifying agents.

UR - http://www.scopus.com/inward/record.url?scp=84922375236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922375236&partnerID=8YFLogxK

U2 - 10.1155/2015/456895

DO - 10.1155/2015/456895

M3 - Article

AN - SCOPUS:84922375236

VL - 2015

JO - Gastroenterology Research and Practice

JF - Gastroenterology Research and Practice

SN - 1687-6121

M1 - 456895

ER -